AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2590626
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) administered twice daily (Group A)
Trial: 2590626
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) administered four times a day (Group B)
Trial: 25764916
Drug: Pre-procedure spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-procedure spinal ultrasound (US) to determine the optimal lumbar level for injection
Trial: 25764916
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group determined the level of injection by palpation
Trial: 24147175
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo treatment during pregnancy)
Trial: 19422464
Drug: Glucose levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose levels in the second quartile (5.3-5.7 mmol L(‐1))
Trial: 19422464
Drug: Glucose levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose levels in the third quartile (5.7-6.6 mmol L(‐1))
Trial: 19422464
Drug: Glucose levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose levels in the fourth quartile (>= 6.6 mmol L(‐1))
Trial: 9551672
Drug: Phlebotomy (500-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlebotomy (500-ml every 2 weeks until iron deficiency achieved) followed by 6-month course of alpha-interferon 2b (3 mu tiw)
Trial: 9551672
Drug: Phlebotomy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phlebotomy followed by interferon therapy
Trial: 7817727
Drug: Women with
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with medical treatment for essential hypertension
Trial: 21199410
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 added to systemic steroid treatment for 2 weeks.
Trial: 21199410
Drug: Systemic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic steroid treatment for 2 weeks (control group).
Trial: 12201869
Drug: INF-alpha 10
RxNorm normalized name: r-INF-alpha
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INF-alpha 10 MU/m2 and LAM 4 mg/kg (max 100 mg) for 6 months, then LAM alone for 6 months
Trial: 2248073
Drug: Moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300 mg daily for the first 5 days, then up to 600 mg)
Trial: 2248073
Drug: Imipramine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (starting at 33 mg, increased to 100 mg/day in the first 5 days, then could be further increased)
Trial: 26411328
Drug: Mitiglinide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitiglinide (10 mg tid) with insulin glargine
Trial: 26411328
Drug: Voglibose (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.2 mg tid) with insulin glargine
Trial: 23181446
Drug: Global secondary
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Global secondary low back pain prevention program (two-hour information session + five weekly 90-min exercise sessions)
Trial: 11994812
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise and lifestyle modification
Trial: 9816650
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 60 micrograms PGE1 over a period of 2 hours
Trial: 7694917
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality graded exposure treatment (N = 10)
Trial: 28107559
Drug: AVX001 (cPLA2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVX001 (cPLA2α inhibitor) at 5% dose level
Trial: 28107559
Drug: AVX001 (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVX001 (combined doses of 3% and 5%)
Trial: 28107559
Drug: AVX001 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVX001 (any dose)
Trial: 19342174
Drug: tricyclic antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tricyclic antidepressant medication
Trial: 19342174
Drug: (cognitive-behavioral) stress-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (cognitive-behavioral) stress-management therapy plus placebo
Trial: 19342174
Drug: stress-management therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stress-management therapy plus antidepressant medication
Trial: 15869575
Drug: High-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity warfarin (INR range 3.0-4.5)
Trial: 15869575
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (warfarin, INR range 2.0-3.0 or aspirin 100 mg/day)
Trial: 9585282
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Trial: 9585282
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Trial: 2696203
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg (oral)
Trial: 2696203
Drug: Verapamil 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 1.6 mg (inhalation)
Trial: 11565519
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg daily
Trial: 15655140
Drug: 6% salicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% salicylic acid gel plus 0.1% tacrolimus ointment
Trial: 15655140
Drug: 6% salicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% salicylic acid gel plus vehicle
Trial: 11860410
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment in H. pylori-positive patients (36 patients)
Trial: 2297284
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d cholesterol diet
Trial: 2297284
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d cholesterol diet
Trial: 856917
Drug: H3ChN2Ch virus
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3ChN2Ch virus vaccine
Trial: 856917
Drug: Heq1N2Ch virus
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heq1N2Ch virus vaccine
Trial: 22876748
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg for three weeks
Trial: 20712805
Drug: morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.1 mg.kg⁻¹
Trial: 20712805
Drug: oxycodone 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxycodone 0.05 mg.kg⁻¹
Trial: 20712805
Drug: oxycodone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxycodone 0.1 mg.kg⁻¹
Trial: 20712805
Drug: oxycodone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxycodone 0.2 mg.kg⁻¹
Trial: 11192337
Drug: Biofeedback-assisted behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback-assisted behavioral treatment
Trial: 11192337
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment with oxybutynin chloride
Trial: 3166825
Drug: All program
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All program components (lifestyle assessment, physician prescription of lifestyle change, educational materials)
Trial: 26392433
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of autologous bone marrow mononuclear cells (BMNC)
Trial: 23723385
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with conventional physical therapy
Trial: 21700945
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril plus indapamide for eligible patients)
Trial: 3451878
Drug: Alinidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine (10 mg i.v. bolus followed by 10 mg h-1 infusion)
Trial: 24402830
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus vinorelbine (1,250 mg orally QD continuously plus 20 mg/m(2)/day IV)
Trial: 24402830
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus capecitabine (1,250 mg orally QD continuously plus 2,000 mg/m(2)/day orally, 2 doses)
Trial: 16456382
Drug: Alpha‐1‐antitrypsin replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha‐1‐antitrypsin replacement therapy
Trial: 12641014
Drug: Paclitaxel-coated drug-eluting
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-coated drug-eluting stent
Trial: 12641014
Drug: Paclitaxel-coated drug-eluting
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-coated drug-eluting stent (NIRx, TAXUS I trial)
Trial: 2576115
Drug: Acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400 mg u.i.d.)
Trial: 2576115
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg u.i.d.)
Trial: 577889
Drug: Two-agent therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-agent therapy (methotrexate and hydrocortisone)
Trial: 577889
Drug: Three-agent therapy
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-agent therapy (methotrexate, hydrocortisone, and cytosine arabinoside)
Trial: 577889
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of two-agent and three-agent therapy
Trial: 7044582
Drug: albendazole 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albendazole 0.4 g (adolescents and adults) or 0.2 g (children)
Trial: 31029925
Drug: Organic beet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic beet leaves and stalk juice (32 mg EAG/100 mL)
Trial: 31029925
Drug: Organic beet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic beet leaves and stalk juice (77.5 mg EAG/100 mL)
Trial: 29322254
Drug: Thermal mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal mineral water treatment for 3 weeks (15 occasions) on top of usual musculoskeletal pain killer treatment
Trial: 29322254
Drug: Traditional musculoskeletal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional musculoskeletal pain killer treatment
Trial: 18436468
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group (Control)
Trial: 1253157
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor immunotherapy
Trial: 29130724
Drug: Probiotics therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics therapy for eight weeks
Trial: 9440718
Drug: Sequential MOPP-ABVD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MOPP-ABVD
Trial: 7866845
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy with cortisone injections
Trial: 7866845
Drug: Standardised conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised conventional and optimised activating treatment
Trial: 2712914
Drug: Endocervical application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocervical application of 0.4 mg prostaglandin E2 (PGE2) gel
Trial: 2712914
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin infusions
Trial: 28289033
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of PZA (>50 mg/kg of body weight)
Trial: 28289033
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of PZA (>80 mg/kg)
Trial: 28289033
Drug: Doses in
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses in the range of 30 to 40 mg/kg of PZA
Trial: 23154555
Drug: First-line erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy
Trial: 19922895
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablet (ODT) 5-mg finasteride
Trial: 19922895
Drug: Standard tablet
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tablet 5-mg finasteride
Trial: 17966839
Drug: Single-dose lonafarnib
RxNorm normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose lonafarnib 100 mg under fasted conditions
Trial: 17966839
Drug: Single-dose lonafarnib
RxNorm normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose lonafarnib 100 mg under fed conditions
Trial: 17966839
Drug: Multiple-dose lonafarnib
RxNorm normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose lonafarnib 200 mg Q 12 H for 28 days under fasted conditions
Trial: 17966839
Drug: Multiple-dose lonafarnib
RxNorm normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-dose lonafarnib 200 mg Q 12 H for 28 days under fed conditions
Trial: 14987883
Drug: Autologous renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous renal tumour cell vaccine (six intradermal applications at 4-week intervals postoperatively)
Trial: 14987883
Drug: Autologous renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous renal tumour cell vaccine
Trial: 29389076
Drug: Bazedoxifene (20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene (20-mg capsule)
Trial: 29389076
Drug: Ibuprofen (600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600-mg tablet)
Trial: 29389076
Drug: Bazedoxifene and
RxNorm normalized name: Bazedoxifene and conjugated estrogen only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bazedoxifene and Ibuprofen (combined)
Trial: 18285414
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose l-T(4) (subclinical thyrotoxicosis arm)
Trial: 18285414
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose l-T(4) (euthyroid arm)
Trial: 15871089
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tl‐weighted and STIR sequences
Trial: 8721699
Drug: Straight pigtail
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Straight pigtail catheter with preset injection rate (Group IA, n = 46)
Trial: 8721699
Drug: Curved pigtail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curved pigtail catheter with preset injection rate (Group IIA, n = 48)
Trial: 8721699
Drug: Straight pigtail
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Straight pigtail catheter with operator defined injection rate (Group IB, n = 49)
Trial: 8721699
Drug: Curved pigtail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curved pigtail catheter with operator defined injection rate (Group IIB, n = 45)
Trial: 27716253
Drug: Nurse-administered IVI
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered IVI
Trial: 27716253
Drug: Physician-administered IVI
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-administered IVI
Trial: 21183910
Drug: cytoflavin intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cytoflavin intravenously in dose 10 ml/day for 5 days
Trial: 21183910
Drug: standard intensive
RxNorm normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard intensive therapy for burns
Trial: 8774297
Drug: Negative media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative media with < 1 pg/mL of endotoxin
Trial: 8774297
Drug: Positive media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive media with > or = 1 pg/mL of endotoxin
Trial: 8774297
Drug: Media with
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Media with > 2 pg/mL of endotoxin
Trial: 1309477
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g citrus pectin added to a 500 kcal meal with 25 mg beta-carotene
Trial: 1309477
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (500 kcal) with 25 mg beta-carotene without pectin
Trial: 6368491
Drug: Regional radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional radiotherapy (RT) followed by weekly injection of vinblastine for 2 years
Trial: 6368491
Drug: Extended RT
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended RT (mantle + para‐aortic + spleen treatment)
Trial: 6368491
Drug: TNI or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNI or combined modality treatment
Trial: 30199273
Drug: Less sensory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less sensory conflict games (e.g., third‐person platformer games, space and flight simulator games)
Trial: 24971923
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint therapy for 30 days
Trial: 10432134
Drug: Topical estradiol
RxNorm normalized name: estradiol Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estradiol (E2) cream and pelvic muscle biofeedback training
Trial: 10432134
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream and pelvic muscle biofeedback training
Trial: 10432134
Drug: Topical estradiol
RxNorm normalized name: estradiol Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estradiol (E2) cream and sham biofeedback
Trial: 10432134
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream and sham biofeedback
Trial: 1844356
Drug: Topical mechlorethamine
RxNorm normalized name: mechlorethamine Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mechlorethamine hydrochloride in aqueous vehicle
Trial: 1844356
Drug: Topical mechlorethamine
RxNorm normalized name: mechlorethamine Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mechlorethamine hydrochloride in ointment vehicle
Trial: 24449682
Drug: Budesonide (1
RxNorm normalized name: budesonide (11.beta.,16.alpha.(S))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (1 mg) via mucosal atomization device (MAD) twice a day for 60 days
Trial: 24449682
Drug: Budesonide via
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide via impregnated nasal saline irrigation (INSI) twice a day for 60 days
Trial: 17571283
Drug: Advicor (1000/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advicor (1000/20 mg)
Trial: 17571283
Drug: Niacin ER
RxNorm normalized name: Niacin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin ER (1000 mg)
Trial: 17571283
Drug: Niacin ER
RxNorm normalized name: Niacin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin ER (1000 mg) + Lovastatin (20 mg)
Trial: 10743483
Drug: High-carbohydrate breakfast
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate breakfast with red pepper (10 g)
Trial: 10743483
Drug: Mixed diet
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed diet with red-pepper appetizer (6 g)